Lemercier Jean-Luc M

SEC source: 0001225208-24-007359 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,685.8054

SEC source: 0001225208-24-005982 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,767.8055

SEC source: 0001225208-24-005888 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,125

Underlying: Common Stock · 7,125 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2027. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-24-005888 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,200

Underlying: Common Stock · 42,200 shares

Expires 2031-05-06

F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-24-005888 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,788.8055

SEC source: 0001225208-24-005888 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,834.8055

F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,709.8055

SEC source: 0001225208-24-005702 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,157 shares

Expires 2028-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,968.8055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-24-005702 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,811.8055

SEC source: 0001225208-24-005437 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,400 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-24-005437 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,848.8055

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

F3 · price: This transaction was executed in multiple trades at prices ranging from $83.740 to $84.725. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-24-005437 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,088.8055

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $84.750 to $84.930. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-24-005437 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,248.8055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

SEC source: 0001225208-24-005005 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,400

Underlying: Common Stock · 14,400 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-24-005005 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,848.8055

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $91.65 to $92.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-24-005005 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,141.8055

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

SEC source: 0001225208-24-005005 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 188,248.8055

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

SEC source: 0001225208-24-004035 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,800

Underlying: Common Stock · 14,400 shares

Expires 2024-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

SEC source: 0001225208-24-004035 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,583.7785

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

F2 · price: This transaction was executed in multiple trades at prices ranging from $91.4500 to $92.0075. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-24-004035 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 187,983.7785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2023.

SEC source: 0001225208-23-007394 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,583.7785

SEC source: 0001225208-23-005917 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,975

Underlying: Common Stock · 1,975 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 11, 2026. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-23-005917 · doc4.xml · derivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,300

Underlying: Common Stock · 13,300 shares

Expires 2030-05-10

F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-23-005917 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,664.7785

F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-23-005617 · doc4.xml · derivative · entry 7

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,640 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 5

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,089.7785

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

SEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,729.7785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

SEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,089.7785

SEC source: 0001225208-23-005617 · doc4.xml · derivative · entry 6

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 920

Underlying: Common Stock · 3,355 shares

Expires 2027-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,193.7785

SEC source: 0001225208-23-005617 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,417.7785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

F1 · price: On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-23-005433 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,062.7785

SEC source: 0001225208-23-005433 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,100.7785

SEC source: 0001225208-23-004761 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,640

Underlying: Common Stock · 6,640 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-004761 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,137.7785

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $82.79 to $83.45 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-004761 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,777.7785

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

SEC source: 0001225208-23-003597 · doc4.xml · derivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,280

Underlying: Common Stock · 6,640 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-23-003597 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,874.8696

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

F2 · price: This transaction was executed in multiple trades at prices ranging from $76.43 to $77.36 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-23-003597 · doc4.xml · nonDerivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,464.8696

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

SEC source: 0001225208-23-003597 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEACLA and JAPAC

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,514.8696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.

SEC source: 0001225208-22-008764 · doc4.xml · derivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,625

Underlying: Common Stock · 7,625 shares

Expires not disclosed

F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on July 7, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on July 7, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

SEC source: 0001225208-22-008764 · doc4.xml · derivative · entry 2

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,500

Underlying: Common Stock · 54,500 shares

Expires 2029-07-06

F2 · derivative.exercise_date: These options were granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.

SEC source: 0001225208-22-008764 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,874.8696

F1 · shares: These restricted stock units were granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

SEC source: 0001225208-22-007136 · doc4.xml · nonDerivative · entry 1

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,756.3402

SEC source: 0001225208-22-006814 · doc4.xml · derivative · entry 7

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,560 shares

Expires 2022-05-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-22-006814 · doc4.xml · nonDerivative · entry 5

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,899.3402

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021.

F3 · price: This transaction was executed in multiple trades at prices ranging from $97.95 to $98.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001225208-22-006814 · doc4.xml · nonDerivative · entry 4

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,459.3402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 29, 2021.

SEC source: 0001225208-22-006814 · doc4.xml · derivative · entry 6

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,531 shares

Expires 2026-05-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

SEC source: 0001225208-22-006814 · doc4.xml · nonDerivative · entry 3

Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,899.3402